Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration

Paula I. Fuller-Carter, Hamed Basiri, Alan R. Harvey, Livia S. Carvalho

Research output: Contribution to journalReview article

1 Citation (Scopus)


Inherited retinal diseases (IRDs) comprise a clinically and genetically heterogeneous group of disorders that can ultimately result in photoreceptor dysfunction/death and vision loss. With over 270 genes known to be involved in IRDs, translation of treatment strategies into clinical applications has been historically difficult. However, in recent years there have been significant advances in basic research findings as well as translational studies, culminating in an increasing number of clinical trials with the ultimate goal of reducing vision loss and associated morbidities. The recent approval of Luxturna® (voretigene neparvovec-rzyl) for Leber congenital amaurosis type 2 (LCA2) prompts a review of the current clinical trials for IRDs, with a particular focus on the importance of adeno-associated virus (AAV)-based gene therapies. The present article reviews the current state of AAV use in gene therapy clinical trials for IRDs, with a brief background on AAV and the reasons behind its dominance in ocular gene therapy. It will also discuss pre-clinical progress in AAV-based therapies aimed at treating other ocular conditions that can have hereditable links, and what alternative technologies are progressing in the same therapeutic space.

Original languageEnglish
Pages (from-to)763-781
Issue number6
Publication statusPublished - Dec 2020

Fingerprint Dive into the research topics of 'Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration'. Together they form a unique fingerprint.

Cite this